Search Result

Isoforms Recommended:	IDH1

Results for "

IDH1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) ATP Synthase (2) Bacterial (1) Endogenous Metabolite (4) Fungal (1) Histone Demethylase (2) Isocitrate Dehydrogenase (IDH) (31) mTOR (2) Reactive Oxygen Species (3) Virus Protease (1)
By Research Areas:	Cancer (34) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas

HY-150238S

IDH1 Inhibitor 7-d2	Isocitrate Dehydrogenase (IDH)	Cancer
IDH1 Inhibitor 7-d₂ is the deuterium labeled IDH1 Inhibitor 7 (HY-150238). IDH1 Inhibitor 7 is an *IDH1* inhibitor with an IC₅₀ of less than 100 nM.

HY-112601

IDH1 Inhibitor 1	Isocitrate Dehydrogenase (IDH)	Cancer
IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-penetrant and selective mutant *IDH1* inhibitor with IC₅₀s of 0.021 μM, 0.045 μM, and 2.52 μM for IDH1 R132H, IDH1 R132C, and IDH1 WT, respectively. Anticancer activity.

HY-143306

IDH1 Inhibitor 5	Isocitrate Dehydrogenase (IDH)	Cancer
IDH1 Inhibitor 5 (compound 2) is an *IDH1* (isocitrate dehydrogenase 1) inhibitor. IDH1 Inhibitor 5 inhibits MOG cells and wild-type IDH1 glioma cells with expressing exogenous mutant IDH1 R132H protein with IC₅₀s of 64.4 and 34.9 nM, respectively.

HY-41648

IDH1 Inhibitor 8

Isocitrate Dehydrogenase (IDH) Cancer

IDH1 Inhibitor 8 (91) is isocitrate dehydrogenase 1 (IDH1) inhibitor. IDH1 Inhibitor 8 can be used for the research of cancer.
HY-107977

IDH1 Inhibitor 3

Isocitrate Dehydrogenase (IDH) Cancer

IDH1 Inhibitor 3 (compound 6f) is a mutant isocitric dehydrogenase 1 (IDH1) inhibitor, with an IC₅₀ of 45 nM for IDH1 R132H.
HY-150238

IDH1 Inhibitor 7

Isocitrate Dehydrogenase (IDH) Cancer

IDH1 Inhibitor 7 (Compound 88) is an IDH1 inhibitor with an IC₅₀ of less than 100 nM.

IDH1 Inhibitor 8	Isocitrate Dehydrogenase (IDH)	Cancer
IDH1 Inhibitor 8 (91) is isocitrate dehydrogenase 1 *(IDH1)* inhibitor. IDH1 Inhibitor 8 can be used for the research of cancer.

IDH1 Inhibitor 3	Isocitrate Dehydrogenase (IDH)	Cancer
IDH1 Inhibitor 3 (compound 6f) is a mutant isocitric dehydrogenase 1 (IDH1) inhibitor, with an IC₅₀ of 45 nM for IDH1 R132H.

IDH1 Inhibitor 7	Isocitrate Dehydrogenase (IDH)	Cancer
IDH1 Inhibitor 7 (Compound 88) is an *IDH1* inhibitor with an IC₅₀ of less than 100 nM.

HY-128661

IDH1 Inhibitor 2	Isocitrate Dehydrogenase (IDH)	Metabolic Disease
IDH1 Inhibitor 2 (compound 13) is a potent wild-type IDH1 inhibitor via a direct covalent modification of His315, with an IC₅₀ of 110 nM.

HY-13972

Mutant IDH1 inhibitor

2 Publications Verification

Isocitrate Dehydrogenase (IDH) Cancer

Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC₅₀ of < 72 nM.

*Mutant IDH1* inhibitor** 2 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC₅₀ of < 72 nM.

HY-149359

*IHMT-IDH1-053*	Isocitrate Dehydrogenase (IDH)	Cancer
IHMT-IDH1-053 (compound 16) is a highly selectivity and irreversible *IDH1-mutant* inhibitor with an IC₅₀ of 4.7 nM for IDH1 R132H. IHMT-IDH1-053 displays high selectivity against IDH1 mutants over IDH1 wt and IDH2 wt/mutants. IHMT-IDH1-053 inhibits 2-hydroxyglutarate (2-HG) production in IDH1 R132H mutant transfected 293T cells (IC₅₀=28 nM). IHMT-IDH1-053 binds to the IDH1 R132H protein in the allosteric pocket adjacent to the NAPDH binding pocket through a covalent bond with residue Cys269. IHMT-IDH1-053 inhibits the proliferation of HT1080 cell line and primary AML cells which both bear IDH1 R132 mutants.

HY-131312

LY3410738 Mutant IDH1-IN-6	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-6 is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC₅₀s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes.

HY-12475

*Mutant IDH1-IN-1* 2 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-1 is a mutant-selective *IDH1* inhibitor with with IC₅₀s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.

HY-114459

*Mutant IDH1-IN-4*	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-4 (compound 434) is an inhibitor of mutant Isocitrate dehydrogenase 1 (IDH 1), with IC₅₀ values of ≤ 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells.

HY-18717

*Mutant IDH1-IN-2* 2 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.

HY-145594

Safusidenib AB-291; DS-1001	Isocitrate Dehydrogenase (IDH)	Cancer
Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective mutant *IDH1* inhibitor. Safusidenib strongly inhibits mutant IDH1 but not wild-type IDH1. Safusidenib impairs tumor activity in chondrosarcoma. Safusidenib exhibits activity against *IDH1R132H, and IDH1R132C* with IC₅₀s of 15, and 130 nM in assays without any preincubation, respectively.

HY-110144

TC-E 5008	Isocitrate Dehydrogenase (IDH)	Cancer
TC-E 5008 is a potent mutant IDH1 inhibitor with K_i values of 190 nM and 120 nM for R132H and R132C IDH1 mutants, respectively. TC-E 5008 exhibits very weak activity against WT-IDH1 with a K_i value of 12.3 μM. TC-E 5008 has anti-proliferative activity on multiple ER positive breast cancer cell lines.

HY-121736

AGI-12026 AGI-026	Isocitrate Dehydrogenase (IDH)	Neurological Disease
AGI-12026 is brain-penetrant dual inhibitor of mutant IDH1 and 2. AGI-12026 shows partial inhibition of the IDH1-R132H homodimer as allosteric modulators. AGI-12026 has the potential for research of glioma.

HY-104036

IDH-305	Isocitrate Dehydrogenase (IDH)	Cancer
IDH-305 is an orally available, mutant-selective and brain-penetrant *IDH1* inhibitor that targets IDH1 (R132) mutation. IDH-305 exhibits greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC₅₀= 27 nM (IDH1 R132H), 28 nM (IDH1 R132C), 6.14 µM (IDH1 WT)).

HY-112289

IDH889	Isocitrate Dehydrogenase (IDH)	Cancer
IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC₅₀s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1 R132H, IDH1 R132C and IDH1 wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC₅₀ of 0.014 μM.

HY-112289B

*(1R)-IDH889*	Isocitrate Dehydrogenase (IDH)	Cancer
(1R)-IDH889 is the inactive isomer of IDH889 (HY-112289), and can be used as an experimental control. IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC₅₀s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1 R132H, IDH1 R132C and IDH1 wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC₅₀ of 0.014 μM.

HY-114226

Olutasidenib 1 Publications Verification FT-2102	Isocitrate Dehydrogenase (IDH)	Cancer Inflammation/Immunology
Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC₅₀ values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) ^[1].

HY-N0328

alpha-Mangostin 3 Publications Verification α-Mangostin	Reactive Oxygen Species Apoptosis Bacterial Fungal Virus Protease	Cancer
alpha-Mangostin (α-Mangostin) is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (IDH1-R132H) with a K_i of 2.85 μM.

HY-19540

GSK864 3 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
GSK864 is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC₅₀ values of 8.8, 15.2 and 16.6 nM.

HY-18948

GSK321 1 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
GSK321 is a potent inhibitor of mutant *isocitrate dehydrogenase 1 (IDH1) enzymes. GSK321 has high inhibitory and selectivity for mutant IDH1* enzymes. GSK321 can be used for the research of acute myeloid leukemia.

HY-143234

mIDH1-IN-1	Isocitrate Dehydrogenase (IDH)	Cancer
mIDH1-IN-1 (compound 43) is a potent and selective *mIDH1* (mutant isocitrate dehydrogenases 1) inhibitor, with an IC₅₀ of 961.5 nM. mIDH1-IN-1 potently inhibits intracellular 2-HG (2-hydroxyglutarate) production in HT1080 cells, with an EC₅₀ of 208.6 ± 8.0 nM. mIDH1-IN-1 shows a significant anti-proliferation activity on IDH1 mutant-U-87 cells, with an IC₅₀ of 41.8 nM. mIDH1-IN-1 is an antitumor agent, and can be used for IDH1 mutated solid tumors research.

HY-104042

Vorasidenib 3 Publications Verification AG-881	Isocitrate Dehydrogenase (IDH)	Cancer
Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC₅₀ ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K.

HY-100020

BAY-1436032

3 Publications Verification

Isocitrate Dehydrogenase (IDH) Cancer

BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.

BAY-1436032 3 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.

HY-128888

(R,R)-GSK321	Isocitrate Dehydrogenase (IDH)	Cancer
(R,R)-GSK321 is a wild-type isocitrate dehydrogenase 1 (WT IDH1) inhibitor with an IC₅₀ value of 120 nM. (R,R)-GSK321 as a mutant R132H IDH1 inhibitor, is an isomer of GSK321 with some wild-type cross reactivity.

HY-129545

DS-1001b 1 Publications Verification	Isocitrate Dehydrogenase (IDH)	Cancer
DS-1001b is a mutant **IDH-1 (Isocitrate Dehydrogenase-1)** inhibitor extracted from patent WO2016052697A1, Example 168, and has antitumor activity.

HY-18082

AGI-5198 Maximum Cited Publications 11 Publications Verification IDH-C35	Isocitrate Dehydrogenase (IDH)	Cancer
AGI-5198 (IDH-C35) is a potent and selective mutant IDH1 R132H inhibitor with an IC₅₀ of 0.07 μM.

HY-136686

IDH-C227

Isocitrate Dehydrogenase (IDH) Cancer

IDH-C227 is a potent and selective IDH1 R132H inhibitor. IDH-C227 has anticancer effcts.

IDH-C227	Isocitrate Dehydrogenase (IDH)	Cancer
IDH-C227 is a potent and selective IDH1 R132H inhibitor. IDH-C227 has anticancer effcts.

HY-N12390

Alternaphenol B2	Isocitrate Dehydrogenase (IDH)	Cancer
Alternaphenol B2 is a selective *IDH1* inhibitor from the coral-derived fungus Parengyodontium album SCSIO SX7W11. Alternaphenol B2 shows inhibitory activity against isocitrate dehydrogenase mutant R132H (IDH1m), with IC₅₀ values of 41.9 μM.

HY-128888B

(S,R)-GSK321	Isocitrate Dehydrogenase (IDH)	Cancer
(S,R)-GSK321 is a potent, selective mutant *IDH1* inhibitor with IC₅₀ values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. (S,R)-GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. (S,R)-GSK321can be used for research of acute myeloid leukemia (AML) and other cancers.

HY-113038B

α-Hydroxyglutaric acid 2-Hydroxyglutarate; 2-Hydroxyglutaric acid; 2-Hydroxypentanedioic acid	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid (2-Hydroxyglutarate) is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases.

HY-113038A

α-Hydroxyglutaric acid disodium 2-Hydroxyglutarate disodium; 2-Hydroxyglutaric acid disodium; 2-Hydroxypentanedioic acid disodium	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases.

HY-113038

D-α-Hydroxyglutaric acid (R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; (R)-2-Hydroxypentanedioic acid	Reactive Oxygen Species ATP Synthase mTOR Endogenous Metabolite	Cancer Inflammation/Immunology Neurological Disease
D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling.

HY-100542

D-α-Hydroxyglutaric acid disodium 1 Publications Verification Disodium (R)-2-hydroxyglutarate	Reactive Oxygen Species ATP Synthase mTOR Endogenous Metabolite	Cancer Inflammation/Immunology Neurological Disease
D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling.

Cat. No.	Product Name	Target	Category

alpha-Mangostin 3 Publications Verification α-Mangostin	Reactive Oxygen Species Apoptosis Bacterial Fungal Virus Protease	Phenols Xanthones Polyphenols Structural Classification other families Plants Source classification Disease Research Fields Cancer Classification of Application Fields
alpha-Mangostin (α-Mangostin) is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (IDH1-R132H) with a K_i of 2.85 μM.

α-Hydroxyglutaric acid 2-Hydroxyglutarate; 2-Hydroxyglutaric acid; 2-Hydroxypentanedioic acid	Histone Demethylase Endogenous Metabolite	Nervous System Disorder Immune System Disorder Endocrine diseases Endogenous metabolite Disease markers
α-Hydroxyglutaric acid (2-Hydroxyglutarate) is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases.

α-Hydroxyglutaric acid disodium 2-Hydroxyglutarate disodium; 2-Hydroxyglutaric acid disodium; 2-Hydroxypentanedioic acid disodium	Histone Demethylase Endogenous Metabolite	Structural Classification Ketones, Aldehydes, Acids Microorganisms Endogenous metabolite Animals Source classification
α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases.

Alternaphenol B2	Isocitrate Dehydrogenase (IDH)	Structural Classification Phenols Polyphenols Microorganisms Source classification
Alternaphenol B2 is a selective *IDH1* inhibitor from the coral-derived fungus Parengyodontium album SCSIO SX7W11. Alternaphenol B2 shows inhibitory activity against isocitrate dehydrogenase mutant R132H (IDH1m), with IC₅₀ values of 41.9 μM.

D-α-Hydroxyglutaric acid (R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; (R)-2-Hydroxypentanedioic acid	Reactive Oxygen Species ATP Synthase mTOR Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Inflammation/Immunology Neurological Disease Anti-aging Source classification Endogenous metabolite Disease markers Endocrine diseases Nervous System Disorder Immune System Disorder
D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling.

Species:	Virus (1) Human (2)
Tag:	His (1)
Source:	HEK293 (2)

Cat. No.	Product Name	Species	Source

Cat. No.	Product Name

Cat. No.	Product Name	Application	Reactivity

IDH1

Inhibitors & Agonists

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products